Effective resolution of daratumumab‐induced false‐positive antibody screening with commercial reagents
Vox Sanguinis · 2026-07 · 121 (7) · 1082-1086
DOI: 10.1111/vox.70251 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vox Sanguinis, online erschienen am 18.03.2026. Verfasst von Han Joo Kim und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Multiple Myeloma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Background and Objectives Daratumumab (DARA), an anti‐CD38 monoclonal antibody used in the treatment of multiple myeloma, frequently causes false‐positive panreactivity in antibody screening tests. The conventional approach to resolve this interference involves treating reagent red blood cells (RBCs) with 0.2 M dithiothreitol (DTT). However, this method is labour‐intensive, may fail to detect clinically significant antibodies and can yield inconsistent results. We aimed to assess the effectiveness of a commercial reagent containing anti‐CD38 Fab fragments as an alternative for mitigating DARA‐related interference. Materials and Methods We retrospectively analysed 22 blood samples from 17 patients. Antibody screening was performed using both DTT‐treated and DaraEx‐treated reagent RBCs. Clinical and laboratory data were reviewed. Additionally, patient samples were spiked with antibodies to evaluate antibody detection.
Results
All samples showed false‐positive panreactivity after DARA treatment. Nineteen samples were negative using both DTT‐ and DaraEx‐treated cells. Three samples remained reactive with DTT‐treated cells but turned negative with DaraEx. These cases were associated with lower serum albumin, impaired renal function and elevated monoclonal protein levels. DaraEx‐treated cells retained reactivity with anti‐E and anti‐D antibodies.
Conclusion
DaraEx consistently and completely removed DARA‐related interference, including in cases where DTT was ineffective. It represents a safe and efficient alternative to DTT for pre‐transfusion antibody screening.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
- Department of Laboratory Medicine, Kangdong Sacred Heart Hospital, Seoul, Republic of Korea.
- Department of Laboratory Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
ORCID-Profile: Han Joo Kim, Suk Won Seo, Yousun Chung, Hyungsuk Kim, Sang-Hyun Hwang, Heung-Bum Oh, Dae-Hyun Ko
Förderung
- National Research Foundation of Korea
Zitieren
APA
Kim, H. J., Seo, S. W., Chung, Y., Kim, H., Hwang, S. H., Oh, H. B., & Ko, D. H. (2026). Effective resolution of daratumumab‐induced false‐positive antibody screening with commercial reagents. Vox Sanguinis, 121(7), 1082-1086. https://doi.org/10.1111/vox.70251
Vancouver
Kim HJ, Seo SW, Chung Y, Kim H, Hwang SH, Oh HB, et al. Effective resolution of daratumumab‐induced false‐positive antibody screening with commercial reagents. Vox Sanguinis. 2026;121(7):1082-1086. doi:10.1111/vox.70251
BibTeX
@article{Kim2026,
author = {Kim, Han Joo and Seo, Suk Won and Chung, Yousun and Kim, Hyungsuk and Hwang, Sang-Hyun and Oh, Heung-Bum and Ko, Dae-Hyun},
title = {Effective resolution of daratumumab‐induced false‐positive antibody screening with commercial reagents},
journal = {Vox Sanguinis},
year = {2026},
volume = {121},
number = {7},
pages = {1082--1086},
doi = {10.1111/vox.70251}
}
EUVIMED